Studies ileal Crohn's disease and how it returns after surgery
Follows adults with ileal Crohn's disease after bowel surgery, collecting samples to study recurrence.
Plain-language title generated from the registry record
Registry title: Ileal Crohn's Disease and Post-operative Outcome: Prospective Cohort Study of the REMIND Group
Key facts
- Where
- Amiens, Bordeaux, Clermont-Ferrand, Clichy, Créteil, Le Kremlin-Bicêtre, Lille, Marseille, Montpellier, Nancy, Nantes, Nice, Paris, Pierre-Bénite, and Strasbourg, FranceSee the 16 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with Crohn's disease who need surgery to remove part of the small and large bowel (an ileocecal resection).
- Age
- 18 years or older (up to 100 years).
- Sex
- Men and women can join.
- Disease stage
- Crohn's disease confirmed by symptoms, scans, endoscopy or tissue tests, needing an ileocecal resection.
Main reasons for not taking part
- Earlier dysplasia or cancer in the ileum or colon
- Unwilling or unable to follow the trial procedures
- Pregnant women
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 100 years old?
Source: NCT03458195, who can take part
Where in France
- Amiens hospitalAmiens, FranceContact: Mathurin Fumery, DrTaking people
- Haut-Lévêque HospitalBordeaux, FranceContact: Matthieu ALLEZ, PrNo longer taking part
- Clermont-Ferrand HospitalClermont-Ferrand, FranceContact: Anthony Buisson, DrTaking people
- Beaujon HospitalClichy, FranceContact: Xavier Treton, DrTaking people
- Henri Mondor HospitalCréteil, FranceContact: Matthieu Uzzan, DrTaking people
- Kremlin-Bicêtre HospitalLe Kremlin-Bicêtre, FranceContact: Franck CarbonnelTaking people
- Lille HospitalLille, FranceContact: Maria NachuryTaking people
- Hôpital Nord - Chu MarseilleMarseille, FranceContact: Mélanie SerreroTaking people
- Montpellier HospitalMontpellier, FranceContact: Pierre Blanc, PrTaking people
- Brabois HospitalNancy, FranceContact: Laurent PEYRIN-BIROULETTaking people
- Nantes HospitalNantes, FranceContact: Arnaud Boureille, DrTaking people
- Archet 2 HospitalNice, FranceContact: Xavier Hebuterne, PrTaking people
- Saint Louis HospitalParis, FranceContact: Matthieu Allez, PrTaking people
- Saint-Antoine HospitalParis, FranceContact: Philippe Seksik, PrTaking people
- South Lyon HospitalPierre-Bénite, FranceContact: Stéphane Nancey, PrTaking people
- Strasbourg HospitalStrasbourg, FranceContact: Matthieu ALLEZ, PrNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Saint-Louis Hospital, Paris, France
- Trial code
- NCT03458195
- Record updated
- 24 April 2026
- Original description
Crohn's disease (CD), a chronic inflammatory process in intestinal segments leads to tissue damage. More than two thirds of CD patients need intestinal resection. Symptomatic clinical recurrence occurs in 60% by 10 years. The principal factors affecting postoperative recurrence are active smoking, penetrating disease, perianal lesions history, prior intestinal resection, small bowel resection extent, and prophylaxis treatment absence.Read full original descriptionShow less
Ileal Crohn's Disease and Post-operative Outcome: Prospective Cohort Study of the REMIND Group
Crohn's disease (CD), a chronic inflammatory process in intestinal segments leads to tissue damage. More than two thirds of CD patients need intestinal resection. Symptomatic clinical recurrence occurs in 60% by 10 years. The principal factors affecting postoperative recurrence are active smoking, penetrating disease, perianal lesions history, prior intestinal resection, small bowel resection extent, and prophylaxis treatment absence.
Ileocolonoscopy within one year of surgery can predict clinical recurrence risk.
Different therapies are proposed after surgery, to prevent post-operative recurrence : Thiopurines, 6-mercaptopurine (positive for clinical and endoscopic postoperative recurrence prevention), Anti-tumour necrosis factor therapy (anti-TNF), the most effective therapy.
Intestinal microbiota acts as a central factor in the CD pathogenesis, and fecal stream role is clearly shown. Various changes in luminal flora with a possible link to local inflammation was also demonstrated. Bacteria associated with postoperative recurrence could be more pathogenic as adherent invasive E coli (AIEC), which could be a pathogen in CD through several mechanisms including increased mucosal colonization, adherence, replication and induction of TNF secretion. Alternatively, postoperative CD recurrence could be linked to a protective commensal species lack, such as Faecalibacterium prausnitzii.
Microscopic inflammation occurs as early as 8 days after anastomosis in the neoterminal ileum mucosa. IL6, IL10 and TGFb levels, measured in neoterminal ileum early after surgery are associated with different rates of postoperative recurrence. It suggests cytokines implication in postoperative recurrence. T cells are major players in the intestinal immune response. The presence at time of surgery and persistence of disease inducing T cell clonal expansions could play an important role in post-operative recurrence.
The main objective is to define a classification of ileal Crohn's Disease based on data integration on a large cohort of patients.
Inclusion: Informed consent obtained before any study-related activities; A diagnosis of CD, based on clinical, radiologic, endoscopic, or histological evidence; Men and women ≥18 years of age; Required surgical intervention consisting in an ileocecal resection.
Exclusion: Previous history of dysplasia or cancer in the ileum or colon; Unwillingness or inability to follow the procedures outlined in the protocol; Pregnant women.